https://www.summitmedicalgroup.com/library/adult_health/sma_piriformis_syndrome_exercises/
Thursday, December 05, 2019
Wednesday, November 13, 2019
Optimum study Ponesimod v teriflunomide
Ponesimod won decisively in this phase 2 study in RRMS. 1333 patients were randomized. Ponesimod group had lower ARR, by 30 percent; less combined unique active lesions (cual) by 56 percent, and less fatigue
Ofatumumab (Novartis) v. teriflunomide in 2 phase3 trials. They had a lower ARR and time to confirmed disability.
Ofatumumab (Novartis) v. teriflunomide in 2 phase3 trials. They had a lower ARR and time to confirmed disability.
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Barkhof F, Kappos L, Wolinsky J. Neurology; 2019; e1778-1786.
Authors analyzed 163 individuals from partly blinded phase II trials of ocre and 1656 from double blind phase 3 trials for MS who underwent q 4 week scans, Control group got interferon Beta in phase 3 trials, and 1/3 also got placebo in pahse 2 trials. Relative to placebo, ocrelizumab produced reduction in MRI activity by week 4. Relative to interferon beta 1a, there were less ARR by week eight.
Authors analyzed 163 individuals from partly blinded phase II trials of ocre and 1656 from double blind phase 3 trials for MS who underwent q 4 week scans, Control group got interferon Beta in phase 3 trials, and 1/3 also got placebo in pahse 2 trials. Relative to placebo, ocrelizumab produced reduction in MRI activity by week 4. Relative to interferon beta 1a, there were less ARR by week eight.
Thursday, May 02, 2019
Subscribe to:
Posts (Atom)